
<!doctype html><html lang="en"> <head><meta charset="utf-8"> 
<title>s800 inconsistencies</title> 
<style>

.gray { background-color:rgba(125, 125, 125, 0.5); } 
.orange { background-color:rgba(210, 180, 180, 0.5); } 

.match { text-decoration: underline; 
/*
  -webkit-text-decoration-color: red;  
  text-decoration-color: red; */
    -webkit-text-decoration-line: overline underline; /* Safari */
   text-decoration-line: overline underline; 
   color:yellow;
/*   font-weight:bold; */
  
  
  } 
.LINNAEUS_only { background-color: rgba(125, 125, 125, 0.5); }
.annotated { background-color:rgba(50, 180, 180, 0.5); } 
.unannotated { background-color:rgba(214, 75, 79, 0.5); } 

.match_species { text-decoration: underline; } 
/*
ul#menu li {
/*  display:inline; 
}
.horizontal { display: inline; border-left: 3px solid darkorange; padding-left: 0.3em; }
.first { border-left: none; padding-left: 0; }
*/
ul#menu li {
list-style-type: circle;
}
table { border-collapse: collapse; } 
th, td { border: 1px solid orange; padding: 4px; } 
th {  cursor: pointer; } 
th:hover { background: yellow; }

html, body, iframe { height: 100%; }

* {
  box-sizing: border-box;
}

.row {
  display: flex;
}


/* Create two equal columns that sits next to each other */
.column {
  flex: 50%;
  padding: 0px;
 /*height: 300px; /* Should be removed. Only for demonstration */
}
/* Create two equal columns that sits next to each other */
.column1 {
  flex: 30%;
  padding: 0px;
 /*height: 300px; /* Should be removed. Only for demonstration */
}
/* Create two equal columns that sits next to each other */
.column2 {
  flex: 70%;
  padding: 0px;
 /*height: 300px; /* Should be removed. Only for demonstration */
}
 
</style></head><body>
<h2>20980510</h2><span class="unannotated">not annotated</span> - <span class="annotated">annotated</span> - <span class="LINNAEUS_only">LINNAEUS only</span><br><hr>Assembly and immunological properties of <span class="annotated ">Newcastle disease virus</span>-like particles containing the <span class="annotated ">respiratory syncytial virus</span> F and G proteins. <br><br><span class="annotated ">Human respiratory syncytial virus</span> (<span class="annotated ">RSV</span>) is a serious respiratory pathogen in <span class="LINNAEUS_only ">infants</span> and young <span class="LINNAEUS_only ">children</span> as well as elderly and immunocompromised populations. However, no <span class="annotated ">RSV</span> vaccines are available. We have explored the potential of virus-like particles (VLPs) as an <span class="annotated ">RSV</span> vaccine candidate. VLPs composed entirely of <span class="annotated ">RSV</span> proteins were produced at levels inadequate for their preparation as immunogens. However, VLPs composed of the <span class="annotated ">Newcastle disease virus</span> (<span class="annotated ">NDV</span>) nucleocapsid and membrane proteins and chimera proteins containing the ectodomains of <span class="annotated ">RSV</span> F and G proteins fused to the transmembrane and cytoplasmic domains of <span class="annotated ">NDV</span> F and HN proteins, respectively, were quantitatively prepared from avian cells. Immunization of <span class="annotated ">mice</span> with these VLPs, without adjuvant, stimulated robust, anti-<span class="annotated ">RSV</span> F and G protein antibody responses. IgG2a/IgG1 ratios were very high, suggesting predominantly T(H)1 responses. In contrast to infectious <span class="annotated ">RSV</span> immunization, neutralization antibody titers were robust and stable for 4 months. Immunization with a single dose of VLPs resulted in the complete protection of <span class="annotated ">mice</span> from <span class="annotated ">RSV</span> replication in lungs. Upon <span class="annotated ">RSV</span> intranasal challenge of VLP-immunized <span class="annotated ">mice</span>, no enhanced lung pathology was observed, in contrast to the pathology observed in <span class="annotated ">mice</span> immunized with formalin-inactivated <span class="annotated ">RSV</span>. These results suggest that these VLPs are effective <span class="annotated ">RSV</span> vaccines in <span class="annotated ">mice</span>, in contrast to other nonreplicating <span class="annotated ">RSV</span> vaccine candidates. 
<br><br><br><hr><h3>Ann file</h3><pre>T1	Species 41 64	Newcastle disease virus<br><br>N1	Reference T1 Taxonomy:11176<br><br>T2	Species 95 122	respiratory syncytial virus<br><br>N2	Reference T2 Taxonomy:12814<br><br>T3	Species 143 176	Human respiratory syncytial virus<br><br>N3	Reference T3 Taxonomy:11250<br><br>T4	Species 178 181	RSV<br><br>N4	Reference T4 Taxonomy:11250<br><br>T5	Species 313 316	RSV<br><br>N5	Reference T5 Taxonomy:11250<br><br>T6	Species 409 412	RSV<br><br>N6	Reference T6 Taxonomy:11250<br><br>T7	Species 458 461	RSV<br><br>N7	Reference T7 Taxonomy:11250<br><br>T8	Species 573 596	Newcastle disease virus<br><br>N8	Reference T8 Taxonomy:11176<br><br>T9	Species 598 601	NDV<br><br>N9	Reference T9 Taxonomy:11176<br><br>T10	Species 689 692	RSV<br><br>N10	Reference T10 Taxonomy:11250<br><br>T11	Species 764 767	NDV<br><br>N11	Reference T11 Taxonomy:11176<br><br>T12	Species 864 868	mice<br><br>N12	Reference T12 Taxonomy:10090<br><br>T13	Species 928 931	RSV<br><br>N13	Reference T13 Taxonomy:11250<br><br>T14	Species 1070 1073	RSV<br><br>N14	Reference T14 Taxonomy:11250<br><br>T15	Species 1235 1239	mice<br><br>N15	Reference T15 Taxonomy:10090<br><br>T16	Species 1245 1248	RSV<br><br>N16	Reference T16 Taxonomy:11250<br><br>T17	Species 1276 1279	RSV<br><br>N17	Reference T17 Taxonomy:11250<br><br>T18	Species 1318 1322	mice<br><br>N18	Reference T18 Taxonomy:10090<br><br>T19	Species 1406 1410	mice<br><br>N19	Reference T19 Taxonomy:10090<br><br>T20	Species 1447 1450	RSV<br><br>N20	Reference T20 Taxonomy:11250<br><br>T21	Species 1504 1507	RSV<br><br>N21	Reference T21 Taxonomy:11250<br><br>T22	Species 1520 1524	mice<br><br>N22	Reference T22 Taxonomy:10090<br><br>T23	Species 1562 1565	RSV<br><br>N23	Reference T23 Taxonomy:11250<br><br></pre></body></html>